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Abstract Use of anti-epidermal growth factor receptor (an-
ti-EGFR) agents has yielded significant advances in the
treatment of patients with metastatic colorectal cancer. In
fact these drugs, which include the monoclonal antibodies
cetuximab and panitumumab, can be delivered both as a
single agent and in combination with chemotherapy, achiev-
ing better survival and quality of life and in some cases also
resectability of metastases. However, these agents can result
in the development of toxicities that are usually different
from those observed with chemotherapy alone. For the
management of these adverse effects, proper knowledge is
mandatory. Skin toxicity is the most frequent adverse effect.
Other toxicities can be observed, such as hypomagnesemia,
gastrointestinal toxicity, and thromboembolic events. Severe
infusion reactions can be life-threatening. For these reasons
a review of anti-EGFR-drug-related toxicity is useful for
clinical practice.
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Introduction
Colorectal cancer (CRC) is one of the leading causes of cancer-
related deaths. In recent decades the integration of different
therapeutic strategies, such as surgery, radiation therapy, and
systemic therapy, has yielded improved overall survival and
quality of life. Systemic therapy includes both chemotherapeu-
tic regimens and targeted drugs. However, the introduction of
new targeted drugs has resulted in the development of specific
toxicities and a radically different tolerability profile compared
with chemotherapy. Because cytotoxic agents are used for
cancer therapy, all early-phase studies were designed to identify
the maximum tolerated dose and the dose-limiting toxicities.
These parameters are based on the close relationship between
the dose and the toxicity frequency and magnitude. In contrast,
the side effects caused by targeted drugs seem to be influenced
by the dose, but a clear relationship has not been defined.
The anti-epidermal growth factor receptor (anti-EGFR)
agents used in CRC treatment are the monoclonal antibodies
cetuximab and panitumumab. For these drugs, the commonest
side effects are related to the expression of EGFR in normal
tissues. Skin, the gastrointestinal tract, and the kidney are all
tissues where EGFR is normally expressed.
Since skin rash, diarrhea, and hypomagnesemia, which
arise during anti-EGFR treatment, seem to be different from
those induced by chemotherapy, this review gathers the most
recent knowledge regarding this topic. Other side effects such
as pulmonary and thromboembolic events are rare with these
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agents, even though they are more associated with other
EGFR inhibitors such as tyrosine kinase inhibitors, which
are used in treatment of other malignancies. For each toxicity,
we report a clinical description, the known pharmacological
mechanisms, and the management. A summary of the biolog-
ical mechanism of the anti-EGFR inhibitors is also included.
Skin Toxicity
Skin toxicity is the commonest side effect observed during the
treatment with anti-EGFR agents. It includes several signs and
symptoms, such as papulopustular rash, xerosis/fissures, pru-
ritus, paronychia, hair changes, and mucositis. The incidence
ranges from 30 % for mucositis to 80 % for skin rash (Fig. 1).
Although less than 20 % of patients have severe symptoms
[1], skin toxicity is visible, often causes physical and emo-
tional discomfort, resulting in a significant impact on quality
of life [2••], andmay lead to dose reduction in 60% of patients
or discontinuation of treatment in 32 % of them [3], with
subsequent worse clinical outcomes and an increase of man-
agement costs.
Pharmacological Mechanisms
The exact mechanism of skin toxicity related to EGFR in-
hibitors is not clearly understood. The coincident inhibition of
receptor activity in tissue that depends on EGFR signaling for
normal functions seems to play a critical role in rash develop-
ment, resulting in impairment of keratinocyte growth and
differentiation and increased apoptosis [4]. There is some
evidence in the literature that these agents may alter the
immune system. More recently, a preclinical model showed
the role of tumor necrosis factor α (TNF-α) and interleukin-1
in the development of skin rash associated with EGFR in-
hibitors, and it suggested a possible therapeutic role for anti-
TNF-α agents [5]. Several studies have aimed to identify
histological and immunohistochemical features of the skin
during therapy with EGFR inhibitors, showing decreased
phosphorylated Akt/phosphatidylinositol 3-kinase pathway
activation. This action has a key role in cell survival and
keratinocyte differentiation [6] in both the epidermis and the
dermis, and also upregulation of p27 in the epidermis of
patients treated with cetuximab, probably leading to growth
inhibition of basal keratinocytes [7]. Moreover, treatment with
EGFR inhibitors induces early differentiation by upregulating
the expression of terminal differentiation markers (keratin 1
and keratin 10) [8]. Another mechanism described during
keratinocyte differentiation is the activation of signal trans-
ducer and activator of transcription 3 in the basal layer of the
epidermis [9], but there are no data regarding the association
between this finding and the skin toxicity caused by EGFR
inhibitors. This could result in greater alterations in both the
epidermis and follicles such as atrophy, which is seen in
Fig. 1 Examples of cutaneous
toxicities: in the clockwise
direction, overgrowth of
eyelashes, paronychia, skin
lesions on the back, and facial
rash
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87.5 % of patients treated with cetuximab and in 50 % of
patients treated with panitumumab, but also dyskeratosis,
dysmaturation, and suppurative folliculitis are quite frequent,
whereas dermal inflammatory infiltrate is less frequent with
cetuximab than with panitumumab. This is probably due to the
lower levels of CD68, CD54, and CD4 seen in these patients
[10•]. In addition, EGFR inhibitors induce lower expression of
cytoskeletal proteins—vinculin and α1-actinin—reducing mi-
gration and invasion [11], whereas in keratinocytes they in-
crease chemokine expression by upregulating extracellular-
signal-regulated kinases 1 and 2. This process, resulting in
enhanced skin inflammation [12], is probably not mediated
by the arachidonic acid/prostaglandin pathway, with recruit-
ment of leukocytes that release enzymes, causing apoptosis
and tissue damage, which is responsible for clinical cutaneous
manifestations. These clinical findings are also know as
PRIDE (papulopustules and or paronychia, regulatory abnor-
malities of hair growth, itching, and dryness due to EGFR
inhibitors) [13].
Clinical Aspects
Clinical signs and symptoms may be divided into three cate-
gories depending on their target: inflammation of the pilose-
baceous follicle, represented by skin rash associated with
EGFR inhibitors, which occurs at an early stage and is fre-
quent; alteration of the skin barrier, which is primarily respon-
sible for xerosis, fissures, and pruritus, which are frequent and
delayed; and lesions of the skin appendages (paronychia,
pyogenic granuloma, hair changes), which are delayed and
less frequent [14•].
Skin rash is the commonest dermatological toxicity, and
affects 85 % of patients treated with cetuximab [15] and 90 %
of patients treated with panitumumab [16]. It usually develops
early during the first week or first month of therapy. Thereafter,
it tends to improve spontaneously despite continued treatment.
It is often confined to seborrheic areas (rich in sebaceous
glands): the mid-facial region, excluding the periocular region
and the upper trunk (typically V-shaped), often extending to
retroauricular areas, the scalp, the nape of the neck, shoulders,
and even the pubis. In some patients it may involve the extrem-
ities [17, 18]. Clinically, it is characterized by a monomorphic
papulopustular eruption which consists of erythematous follic-
ular papules that evolve into pustules, sometimes coalescent,
thus forming inflammatory plaques, which may become
infected, usually with Staphylococcus aureus, and form yellow
crusts [7]. However, evolution from pustules to crust formation
is not necessarily a sign of infection, but corresponds to the
drying out of the exudates on the surface of the epidermis.
Comedones and hyperseborrhea do not occur [19]. Histological
analysis reveals a superficial inflammatory cell infiltrate around
the follicular infundibulum. Later, an influx of neutrophils
causes the rupture of the follicle and the epithelial lining [20].
This histological picture corresponds to superficial aseptic neu-
trophilic suppurative folliculitis associated with atrophy of the
stratum corneum. The pustular appearance and the clinical and
histological differences suggest that this rash is not acne. So
terms such as “acneiform” and “acne-like” should be avoided.
Skin xerosis is present in up to 35 % of patients receiving
EGFR inhibitor therapy. Unlike skin rash, it generally has a late
onset after around 30–60 days or more but persists throughout
treatment with EGFR inhibitors. It manifests itself in the
form of dry, squamous skin, often accompanying or following
papulopustular rash. The xerosis may evolve to chronic
asteatotic eczema (in one third of cases), and may be associated
with painful fissures at the fingertips, palms, or knuckles and
on the soles, which may become infected. Some patients
experience dryness of the vagina and perineum, causing
discomfort [17]. In physiopathological terms, skin xerosis
seems to be linked to the abnormal differentiation of
keratinocytes, which is associated with a reduction in the
synthesis of loricrin—a protein located in the corneocyte enve-
lope and which plays a key role in maintaining the integrity of
the skin barrier [21].
Pruritus occurs in about half of all patients treated with
EGFR inhibitors, having a relatively strong impact on their
health-related quality of life. Generally, it is associated with
papulopustular rash, but can also occur without rash, as a
consequence of dry skin [22]. Pruritus caused by the chronic-
ity of xerosis can also continue by an increase in the number of
dermal mast cells—histamine-releasing cells—identified dur-
ing EGFR inhibitor treatment [23].
Nail and periungual toxicity occur in 10-20 % of patients in
general after 2 months or more of EGFR inhibitor therapy and
consist mainly of nail fold inflammation (paronychia) charac-
terized by a red, warm, painful border around the nail, some-
times associated with serous discharge. Periungual pyogenic
granuloma-like lesions may complicate paronychia, leading to
pain and functional limitations. Also onycholysis or onycho-
dystrophy may result as a consequence of nail matrix inflam-
mation [22]. This clinical presentation may be aggravated by
infection due to S. aureus, Gram-negative bacilli, or more
rarely, Candida albicans. It must be suspected if the patient
experiences intense, pulsatile pain and a buildup of pressure
and if crusts appear [24]. The other ungual anomalies reported
refer to the stoppage or slowing of nail growth, fine, fragile, or
brittle nails, and onycholysis (detachment of the ungual bed of a
distolateral origin) [13].
Hair changes usually occur 2-5 months after the start of
treatment. They occur in approximately 50 % of patients
treated with EGFR inhibitors, and may include trichomegaly
and hypertrichosis of eyelashes, often presenting as facial
hirsutism, and also the texture of the facial and scalp hair
can change and become wavy, fine, and brittle. Slower growth
and alopecia are regularly observed. They generally resolve
spontaneously after discontinuation of therapy [17].
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Finally, the commonest oral complication is mucositis,
presenting as broad areas of erythema or aphthous-like
stomatitis [25], whereas severe mucositis and other oral side
effects are infrequent.
Management of Skin Toxicity
Although skin toxicity is the most frequent side effect and
impacts a very large number of patients with CRC treated
with EGFR inhibitors, there are only a few controlled stud-
ies in the literature to guide best practice for management.
Mostly they are based on the experience of clinicians, case
reports, and nonrandomized studies with a small sample
size. In the absence of definitive evidence from randomized
trials, the Multinational Association of Supportive Care in
Cancer (MASCC) has recently reviewed pertinent studies in
the literature using established criteria in order to develop
first-generation recommendations for dermatological toxic-
ities associated with EGFR inhibitors [22]. An group of
Italian experts has presented recommendations for the man-
agement of each type of skin toxicity during treatment with
cetuximab, on the basis of a review of literature, to improve
compliance and outcomes of patients treated with EGFR
inhibitors [26].
The reactive treatment of skin rash depends on toxicity
severity, evaluated by version 4.0 of the National Cancer
Institute (NCI) Common Terminology Criteria for Adverse
Events (CTCAE) scale, which is the reference severity scale
used in clinical trials to classify cutaneous side effects related to
EGFR inhibitors. For grade 1 (characterized by papulopustules
or symptom-free erythema), no specific treatment is recom-
mended, whereas grade 2 (characterized by eruption with pap-
ules or pustules covering less than 50 % of the body surface,
with symptoms that do not interfere with daily activities) can be
treated with topical antibiotherapy (clindamycin 1 % gel, eryth-
romycin 3 % gel, or metronidazole 1 % gel) two times a day
until it improves to grade 1, and for the pustule-prevalent type,
orally administered tetracycline (minocycline 100 mg/day,
doxycycline 100 mg/day) can be used for 4 weeks. For grade
3 toxicity (characterized by eruption with papules or pustules
covering more than 50 % of the body surface, with symptoms
that interfere with daily activities) it is recommended to inter-
rupt treatment for less than 21 days and if no improvement
occurs to discontinue therapy. Moreover, topical treatment as
for grade 2 should be used together with systemic treatment
with orally administered tetracycline for 4 weeks and oral
corticosteroids (prednisone 0.5 mg/kg) for up to 10 days. For
nonresponsive and grade 4 patients (generalized rash or severe
symptoms that require emergency treatment), systemic treat-
ment with an oral retinoid (isotretinoin 0.3-0.5 mg/kg), intra-
venous corticosteroids, intravenous antibiotics (amoxicillin/
clavulanic acid, gentamicin), intravenous antihistamines, and
hydration or hospitalization can be considered. However, a new
classification system specifically for side effects related to
EGFR inhibitors has been put forward by a group of experts,
the MASCC, and is based on the severity of local involvement
of folliculitis and not on the degree of extension [27]. A recent
prospective study comparing this classification system
(MESTT) with version 4.0 of CTCAE has shown that the
correlation is excellent for rash, pruritus, xerosis, onycholysis,
and alopecia, but there is an increase in toxicity grade with the
MESTT classification for paronychia [28•]. Although the
MESTT classification seems to be more precise, it is also more
difficult to put into daily practice. Moreover, it has still to be
validated. In contrast, even though it is not yet sufficiently
appropriate for assessing the skin toxicity of EGFR inhibitors,
version 4.0 of CTCAE has already been validated and is widely
used in current practice.
Interesting data have been presented on the beneficial effect
of a vitamin K1 cream in prevention and treatment of skin rash
induced by EGFR inhibitors. A reduction of the severity of
skin rash related to EGFR inhibitors to grade 1 in 2.3 weeks
[29], a lower incidence of skin rash of all grades, and the
absence of severe forms when vitamin K1 cream was used for
prophylaxis were reported [30]. All published reports are,
however, based on studies without a control group.
In the prophylactic treatment, 1 % hydrocortisone com-
bined with moisturizer sunscreen and 100 mg minocycline
twice daily for the first 6 weeks or 100 mg doxycycline
twice daily for the first 8 weeks are recommended. This is
supported by randomized phase III trials which demonstrated a
significant decrease of skin rash severity [31, 32]. A recent
phase II randomized trial [33•] comparing preemptive skin
toxicity therapy with reactive treatment in 115 patients with
CRC treated with panitumumab combined with irinotecan or
irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI)
has shown a significant reduction of approximately 50% in the
incidence of toxicities greater than grade 2 in favor of the
preemptive group versus the reactive group [29 % vs 62 %;
hazard ratio (HR) 0.3]. This preemptive strategy had no impact
on the efficacy of the antitumoral treatment. There were no
significant differences in overall response rate, disease control
rate, and median progression-free survival (PFS) (4.7 months
vs 4.1 months; HR 1). On the basis of the high frequency of
skin rash and the early development during treatment with
EGFR inhibitors, preventive/prophylactic management can
be recommended [22].
No randomized trials studying the prevention or treatment
of skin xerosis are in progress. Preventive strategies are im-
portant, including the use of tepid water, bath oils, or mild
moisturizing soaps without fragrances for bathing. It is also
important to avoid alcohol-containing lotions and direct sun
exposure [34]. Moderate xerosis may be treated using mois-
turizing and emollient creams which contain urea, colloid
oatmeal, or ammonium lactate and lactic acid for scaly areas.
For severe xerosis, topical steroid creams may be necessary
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[35, 36]. If there are fissures, thick moisturizing or zinc oxide
creams may be applied. Steroid tape and hydrocolloid dress-
ing are recommended for painful erythematous areas [37].
Even though there are no clinical trials in the literature
evaluating treatment of pruritus induced by EGFR inhibi-
tors, current guidelines recommend nonsedating second-
generation antihistamines as a first approach, and an
antiepilectic agent such as pregabalin or gabapentin as
second-line treatment. Recent evidence has shown the effi-
cacy of aprepitant in reducing erlotinib-induced pruritus
[38], but no evidence exists for other EGFR inhibitors.
Paronychia is a difficult side effect to treat and mostly
occurs after several months of treatment. There are no
randomized trials investigating treatment of paronychia.
Recommendations are based on experience, expert opinion,
and case reports. It is very important to minimize periungual
trauma (wearing comfortable shoes and avoiding aggressive
pedicure), decrease inflammation, and prevent superinfec-
tion (use of topical corticosteroids and an anti-inflammatory
dose of tetracycline is recommended) [39–46].
In the management of hirsutism, topically administered
eflornithine cream has been studied in a randomized clinical
trial. It was well tolerated and resulted in a significant
improvement of quality of life [47]. Minoxidil has been
found to be effective in treating nonscarring alopecia.
Topically administered hydrocortisone (0.2 %), steroid
shampoo, and class 1 steroid lotions [19] and mild shampoo
followed by antibiotic spray have recently been reported to
be effective in prevention and management aimed at reduc-
ing inflammation in scarring alopecia [48] .
Finally, the management of mucositis induced by EGFR
inhibitors is based on the MASCC guidelines. These recom-
mend assessing the oral mucosa prior to and during treatment.
Mucositis-associated pain is aggressively treated with topical
and systemic analgesics and sometimes opioids. Moreover,
minocycline and doxycycline may be indicated for manage-
ment of oral aphthous lesions [49]. Specific treatment is
needed if specific oral infections such as candidiasis, herpes
virus reactivation, and mucositis are diagnosed.
In conclusion, skin toxicity is a common adverse effect of
EGFR-targeted agents. Current data indicate that both the
onset and the intensity of rash are related to drug exposure,
although the cause of rash remains unclear. Skin toxicity does
not affect all patients and there is a high level of interpatient
variability. This could be due to the methods used to assess
and categorize rash. Susceptibility to both rash and the phar-
macological effects of EGFR-targeted agents could be linked
to polymorphic variations in the EGFR gene [1].
Relationship Between Skin Rash and Efficacy
Several studies have investigated the relationship between rash
and clinical outcome with both cetuximab and panitumumab.
Patients with metastatic CRC who developed skin rash during
treatment with EGFR inhibitors had a better outcome than
those who had grade 0 rash. Particularly, Saltz et al. [50]
reported that 19.25 % of patients treated with cetuximab in
combination with irinotecan had no rash and a median survival
of 4.1 months, compared with 6.2 months for those with grade
1 rash, 10.5 months for those with grade 2 rash, and
14.9 months for those with grade 3 rash (no rash vs grade 3
rash, p<0.0001). Similar results were observed in patients
treated with cetuximab alone [51]. In a randomized phase II
trial of cetuximab plus irinotecan versus chemotherapy alone,
9.4 % of patients receiving the experimental treatment devel-
oped grade 3 rash, compared with 5.2 % of patients in the
control arm. In addition, a higher response rate and median
survival was associated with the severity of rash [52]. The
EVEREST trial is based on this evidence, and showed a strong
association between skin rash and clinical outcome in patients
with metastatic CRC receiving cetuximab treatment (and also
the reported relationship between rash severity and drug dose
exposure) [1, 24, 38, 53]. The EVEREST trial investigated the
effect of cetuximab dose escalation in those who developed no
or mild skin reaction after 21 days of treatment with irinotecan
plus cetuximab at a standard dose. Dose escalation was asso-
ciated with higher intensity of rash of grade higher than 2
(59 % vs 38 %), and higher disease control rate (70 % vs
58%) for K-Ras wild-type patients compared with the standard
dose. This effect suggests that cetuximab dose escalation im-
proves the efficacy of therapy in patients with no or minimal
skin rash [54]. Also for panitumumab a significant relationship
between skin rash severity and clinical outcome has been
reported. Skin rash was observed in about 90 % of patients
with metastatic CRC treated with panitumumab compared
with 9 % of patients in the best support group [16]. Among
patients in the panitumumab arm, 86 % of responders had a
maximum skin rash severity of grade 2–4, and the remaining
14 % of responders had a grade 1 rash. PFS and overall
survival were better for patients with grade 2–4 rash than for
patients with grade 1 rash (PFS HR 0.62; overall survival HR
0.59). A subsequent trial which considered the K-Rasmutation
status of patients confirmed the association between skin rash
severity as measured by both the CTCAE grading system and
dermatology life quality index scores and PFS, overall surviv-
al, disease-related symptoms, and health-related quality of life
only for K-Ras wild-type patients treated with panitumumab,
and not for the mutant K-Ras group [55]. Although skin rash is
a marker of clinical benefit in patients with metastatic CRC
treated with EGFR inhibitors, its use as a predictor factor of
response in clinical practice has several limitations: it was not
possible to select patients who may derive greater benefit from
EGFR inhibitor therapy prior to the treatment; moreover, only
a subgroup of patients who developed skin rash during EGFR
treatment derived a significant survival benefit from therapy,
probably because the amount of drug required to cause rash is
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less than that required to induce tumor inhibition [56]. Finally,
a direct relationship between EGFR blockade and skin rash
development could not be the only possible explanation for
this clinical association. For example, EGFR polymorphisms
might increase the genetic susceptibility of some patients to
develop rash and tumor response independently as described
by Perea et al. [57]. Skin rash could be considered a factor
correlated with a better prognosis rather than a predictor of
response. It might be that the occurrence of rash reflects a
patient’s ability to develop an inflammatory reaction in re-
sponse to damage caused by EGFR inhibitors in the skin,
irrespective of the effect of EGFR inhibition in the tumor.
Therefore, since our understanding of cause of rash remains
limited, more studies on this are required.
Hypomagnesemia
Hypomagnesemia is a frequent adverse event (often ignored
in many studies) reported during treatment with EGFR in-
hibitors, both with cetuximab (Erbitux®; ImClone Systems,
New York, NY, USA) and with panitumumab [58]. It has not
been described with small molecules targeting the EGFR
pathway, such as gefitinib and erlotinib. It can be considered
as an antibody-specific phenomenon. Schrag et al. [59] first
reported on a patient with cetuximab-induced hypomagnese-
mia associated with significant clinical symptoms as fatigue
and paresthesias. A recent meta-analysis [60] revealed that
36.5 % of patients treated with cetuximab for various cancers
had hypomagnesemia of any grade, and 5.6 % had grade 3–4
hypomagnesemia. A similar result can be observed in the
meta-analysis of Petrelli et al. [61], which included only
prospective randomized phase III trials comparing cetuximab
or panitumumab with standard chemotherapy or best support-
ive care. It showed a significantly higher risk of developing
hypomagnesemia in the population treated with EGFR inhib-
itors (relative risk 5.83). Finally, the meta-analysis of Nie et al.
[62] also reported a significantly higher incidence of severe
hypomagnesemia (grade 3–4) in patients with metastatic CRC
treated with the EGFR inhibitors cetuximab and panitumumab
compared with standard chemotherapy (27.2 % vs 5.6 %;
odds ratio 6.73).
Pharmacological Mechanism
The mechanism behind this toxicity has been described by
Groenestege et al. [63]. EGFR inhibitors are strongly
expressed in the kidney, particularly in the ascending limb of
the loop of Henle, where 70 % of filtered magnesium is
reabsorbed. EGFR blockade may interfere with magnesium
transport, provoking renal wasting. The blockade of EGFR in
the nephron would reversibly impair the function of the pro-
tein TRPM6, a member of the transient receptor potential
family of the cation channels localized along the apical mem-
brane of the loop of Henle and the distal convoluted tubule
(where EGFR is overexpressed). This is involved in active
transport of extracellular magnesium [64, 65]. Furthermore,
Tejpar at al. [66] showed using 24-h urine analysis and intra-
venous magnesium load test efficacy that patients treated with
monoclonal antibody EGFR inhibitors had defects in renal
magnesium reabsorption. However, there is no direct evidence
to support this hypothesis. The effects of EGFR blockade on
magnesium absorption from the gut (where EGFR and
TRPM6 are expressed) cannot be excluded. The same hypoth-
esis of “renal tubular damage” was previously used to explain
the phenomenon of “hypomagnesemic hypocalcemia,” which
was subsequently attributed to parathyroid hormone
unresponsiveness in the presence of low serum magnesium
levels [67]. According to this hypothesis, hypocalcemia is a
secondary effect of low serum magnesium levels via periph-
eral blockade of parathyroid hormone. Correction of hypo-
magnesemia would restore parathyroid hormone responsive-
ness, resulting in a restoration of the equilibrium [68]. Finally,
a homolog of TRPM6 protein, TRPM7, has recently been
associated not only with magnesium homeostasis, but also
with CRC pathogenesis and tumor growth [69]. This might
explain a possible linkage between hypomagnesemia related
to EGFR inhibitors and tumor progression, which needs to be
explored in further studies.
Clinical Aspects
Hypomagnesemia may be divided into different clinical sever-
ity classes according to CTCAE version 4.0. The hypomagne-
semia observed during treatment with EGFR inhibitors is
mostly grade 1–2. Patients are often completely asymptomatic
or have minimal symptoms such as fatigue. High-grade hypo-
magnesemia (grade 3, magnesium concentration between 0.7
and 0.9 mg/dl; grade 4, magnesium concentration below
0.7 mg/dl) has been reported in 10–15 % of patients treated
with cetuximab, and in 3–6 % of patients treated with
panitumumab [16]. The respective risk seems to be associated
with the duration of treatment (6 %, 23%, and 47% in patients
receiving cetuximab treatment for less than 3 months, for
3-6 months, and for more than 6 months, respectively) [68].
Severe hypomagnesemia is generally associated with
nonspecific symptoms such as irritability, paresthesias, som-
nolence, confusion, temporospatial disorientation, and severe
fatigue. These symptoms could easily be attributed to the
underlying tumor or to previous/concomitant chemotherapy
[70]. Magnesium is an important component of GTPase and
a cofactor for Na/K-ATPase, adenylyl cyclase, and kinases.
As a result, severe hypomagnesemia can induce cardiac
arhythmia, coronary artery vasospasm, and sudden death.
Appropriate and aggressive replacement of magnesium is rec-
ommended [71].
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Management
Treatment of severe hypomagnesemia consists of intrave-
nous supplementation of magnesium at doses of 6–10 g
MgSO4 daily or two to three times a week. Oral supplemen-
tation is mostly insufficient. Magnesium supplementation
also results in normalization of serum calcium levels.
Discontinuation of EGFR inhibitor therapy led to the reso-
lution of hypomagnesemia in all cases [68]. However, in all
patients receiving EGFR inhibitor treatment, magnesium
levels should be monitored every 4-8 weeks until 4-
8 weeks after the last therapy.
Relationship Between Toxicity and Efficacy
Some trials explored the relationship between hypomagne-
semia related to EGFR inhibitors and the clinical efficacy of
therapy, showing conflicting results. A recent retrospective
analysis [72] of 68 patients with metastatic CRC treated
with cetuximab and irinotecan showed a higher response
rate, a longer time to progression, and longer overall sur-
vival in 25 patients, with more than 20 % decrease in
magnesium levels compared with those patients with minor
decrease of serum magnesium levels during treatment (re-
sponse rate 64 % vs 25.6 %, p=0.04; time to progression
6 months vs 3.6 months, p=0.0001; overall survival
10.7 months vs 8.9 months, p=0.021). A similar result
was observed in a subsequent trial [73••] with 143 patients
with K-Ras wild-type metastatic CRC receiving the same
therapy (irinotecan and cetuximab). Patients with an early
decrease of magnesium levels of more than 50 % compared
with the basal level had a higher tumor response (55.8 % vs
16.7 %, P<0.0001), a longer time to progression (6.3 months
vs 3.6 months, P<0.0001), and a longer median overall
survival (11.0 months vs 8.1 months, P=0.002). However,
another retrospective analysis [74], exploring the associa-
tion between hypomagnesemia and outcome in the NCIC
Clinical Trials Group/Australasian Gastro-Intestinal Trials
Group CO.17 clinical trial, showed that higher grade of
hypomagnesemia and greater percent reduction in magne-
sium concentration at day 28 predict worse survival in
patients treated with cetuximab in both the K-Ras wild-
type population and the mutant population. We have to
conclude that the results are conflicting.
Gastrointestinal Toxicity
Gastrointestinal toxicity is frequent during EGFR inhibitor
therapy, including nausea and vomiting, abdominal pain, con-
stipation, and diarrhea. Mostly, mild to moderate grades are
reported; in 2-3 % of patients it can be severe. A significantly
higher incidence of severe diarrhea (about 15-17 % of
patients) has been reported when cetuximab or panitumumab
is given in combination with chemotherapy, particularly the
irinotecan regimen (Crystal trial [75], 15 % vs 10.5 %; and
Peeters trial [76], 14 % vs 10 %), even though the same
incidence of grade 3–4 diarrhea was observed with the addi-
tion of panitumumab to the combination of leucovorin, 5-
fluorouracil, and oxaliplatin [77••]. Finally, a recent meta-
analysis [62] showed a significant increase of grade 3–4
adverse events with EGFR inhibitors plus chemotherapy
compared with chemotherapy alone in patients with met-
astatic CRC, including severe diarrhea (62.3 % vs 55.7 %;
odds ratio 1.36). At present, the exact mechanism behind
this toxicity is not clearly understood. It seems to be
associated with blockade of EGFR activity in the gastro-
intestinal tract. EGFR is overexpressed and plays an im-
portant role in cell proliferation and differentiation. It also
regulates cation channels involved in active transport of
extracellular ions and intestinal secretions. Furthermore,
the STEPP trial [33•], which explored the impact of
preemptive treatment with doxycycline in patients with
metastatic CRC, showed a significant reduction of both
skin and nonskin toxicity (such as diarrhea and dehydra-
tion) in the preemptive group compared with the reactive
control group, suggesting that diarrhea induced by the
combination of EGFR inhibitors and chemotherapy has
an inflammatory or infectious component that is poten-
tially improved with the use of doxycycline, the only
systemic agent administered. However, further studies
are needed to evaluate the use of doxycycline for treat-
ment of diarrhea induced by the combination of EGFR
inhibitors and chemotherapy. Management of severe diar-
rhea should be aggressive, including use of loperamide or
diphenoxylate, rehydration, and electrolyte replacement.
Sometimes hospitalization is required.
Infusion Reaction
Even though infusion reaction is not a frequent side effect
observed during EGFR inhibitor therapy, it is considered the
most life-threatening side effect. Infusion reactions of any
grade have been reported in about 10 % of patients treated
with cetuximab and in 4 % of patients treated with
panitumumab. Severe reactions (grade 3–4, NCI Common
Toxicity Criteria, version 2) occurred in 4 % of patients
treated with cetuximab and in less than 1 % of patients
treated with panitumumab. In contrast to panitumumab ther-
apy, cetuximab therapy requires premedication prior to in-
fusion. Most severe reactions with cetuximab usually occur
a few minutes after the first infusion, but 33 % may be
observed after the second dose, and rarely with subsequent
therapies. The physiopathological mechanism underlying a
severe infusion reaction seems to be associated with IgE-
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mediated anaphylaxis, which would affect patients who had
IgE antibodies prior to treatment, as shown by Chung et al.
[78]. In this trial, IgE antibodies against cetuximab were
detected in blood samples of 68 % of patients who had
infusion reaction, compared with 2 % of those without
reaction (p<0.001). Moreover, IgE antibodies were discov-
ered to be specific for α-1,3-galactose, expressed on the
Fab portion of cetuximab heavy chain. So subsequent
reexposure to the antigen would cross-link the Fab portion
of IgE molecules, activating the mast cells or basophils and
triggering the release of clinical mediators. A phase III trial
of panitumumab showed that neutralizing antibodies were
detected in only 1.4 % of patients who had an infusion
reaction. The role of these in the pathogenesis of reactions
and the effective mechanism behind this have yet to be
understood. The management of mild-to-moderate infusion
reaction consists of prompt interruption of infusion and
antihistamine administration. After remission of clinical
symptoms, the treatment can be continued at 50 % of the
standard rate. Premedication with antihistamines and ste-
roids is mandatory prior to the first cetuximab therapy, and
is strongly recommended prior to subsequent therapies. It
seems to reduce the cetuximab-related infusion reactions as
shown by Siena et al. [79•]. No premedication is recom-
mended prior to panitumumab therapy. Finally, Nielsen et
al. [80] described two patients with grade 2 reaction who
were rechallenged with cetuximab. Antihistamines and ste-
roids prior to the next therapy were given without reaction.
There are also limited data on rechallenge with an alterna-
tive EGFR inhibitor. Rechallenge with panitumumab with-
out any premedication in patients who during infusion de-
veloped hypersensitivity reactions to cetuximab (11 cases)
and vice versa (two cases) [81] showed no evidence of acute
reaction [82, 83].
Pulmonary Toxicity
Adverse pulmonary reactions related to EGFR inhibitors are
rare. As discussed already, these drugs can trigger a hyper-
sensitivity reaction during drug infusion. In the case of
respiratory symptoms, anaphylactic reactions have been
observed with rapid onset of airway obstruction (bron-
chospasms, stridor, hoarseness). The use of premedication
is useful in preventing these episodes. Severe reactions re-
quire immediate interruption of infusion and use of broncho-
dilators, antihistamines, and corticosteroids. The incidence of
severe infusion reactions is approximately 3 % with
cetuximab and 0.1 % with panitumumab [84].
Another clinical entity described with the use of
cetuximab is bronchiolitis [85]. Pulmonary fibrosis has
been rarely associated with cetuximab and panitumumab
[86].
Conclusions
EGFR inhibition is one of the most important strategies for
the treatment of patients with metastatic CRC. The intro-
duction of the monoclonal antibodies cetuximab and
panitumumab both as a single agent and in combination
with chemotherapy has resulted in improvement of clinical
outcomes in this setting. These advantages often include
improvement in quality of life, but this effect could be
compromised by toxicities related to EGFR inhibitors.
Skin toxicity is the most frequent side effect observed.
It seems to be related to the expression of EGFR in the
skin tissue. Some strategies are known to prevent and
manage its onset. It does not usually require interruption
of treatment except for severe manifestations with com-
plications. However, proper management is essential to
avoid delay or suspension of treatment and impairment
of quality of life. Some studies have highlighted a pos-
itive relationship between skin rash and clinical
outcomes.
Hypomagnesemia is related to the effect of EGFR func-
tion on magnesium reabsorption in the kidney. Its manage-
ment consists of magnesium supplementation only in severe
cases.
Gastrointestinal toxicity, such as diarrhea, and thrombo-
embolic events can be a consequence of chemotherapy
alone. In the treatment regimens including the combination
of chemotherapy and the anti-EGFR monoclonal antibodies,
a synergism has been recognized for this toxicity.
Finally, infusion reactions are rare events, but can be
lethal. Cetuximab seems to be more associated with
these events than panitumumab. An IgE-mediated ana-
phylaxis could explain this phenomenon. Management
needs to be immediate since the onset is usually sudden.
The opportunity of rechallenge after these events is
under discussion.
Only in a few cases does the anti-EGFR-drug-related
toxicity lead to withholding of treatment. Rarely, it leads
to other severe complications. For this reason, proper man-
agement of these toxicities is mandatory to achieve full
delivery of planned treatment and to not compromise quality
of life.
Compliance with Ethics Guidelines
Conflict of Interest Christian Rolfo declares he has no conflict of
interest.
Giuseppe Bronte declares he has no conflict of interest.
Francesco Passiglia declares he has no conflict of interest.
Konstantinos Papadimitriou declares he has no conflict of interest.
Antonio Russo declares he has no conflict of interest.
Marc Peeters has received a consulting fee/honorarium from Sanofi,
Roche, and Amgen, has received compensation for a board member-
ship from Amgen and Sanofi, is supported by a grant from Amgen, and
has received payment for lectures, including service on speakers bu-
reaus, from Amgen and Sanofi.
Curr Colorectal Cancer Rep (2013) 9:250–260 257
Human and Animal Rights and Informed Consent This article
does not contain any studies with human or animal subjects performed
by any of the authors.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-
targeted agents: is there a silver lining? J Clin Oncol. 2005;23:5235–
46.
2. •• Joshi SS, Ortiz S, Witherspoon JN, et al. Effects of epidermal
growth factor receptor inhibitor-induced dermatologic toxicities on
quality of life. Cancer. 2010;116:3916–23. This is one of few
studies evaluating the impact of skin toxicity on quality of life by
specific questionnaires.
3. Boone SL, Rademaker A, Liu D, et al. Impact and management of
skin toxicity associated with anti-epidermal growth factor receptor
therapy: survey results. Oncology. 2007;72:152–9.
4. Giovannini M, Gregorc V, Belli C, et al. Clinical significance of skin
toxicity due to EGFR-targeted therapies. J Oncol. 2009;2009:849051.
5. Surguladze D, Deevi D, Claros N, et al. Tumor necrosis factor-
alpha and interleukin-1 antagonists alleviate inflammatory skin
changes associated with epidermal growth factor receptor antibody
therapy in mice. Cancer Res. 2009;69:5643–7.
6. Thrash BR,Menges CW, Pierce RH,McCance DJ. AKT1 provides an
essential survival signal required for differentiation and stratification
of primary human keratinocytes. J Biol Chem. 2006;281:12155–62.
7. Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in
cancer patients treated with the antiepidermal growth factor recep-
tor antibody C225. Br J Dermatol. 2001;144:1169–76.
8. Peus D, Hamacher L, Pittelkow MR. EGF-receptor tyrosine kinase
inhibition induces keratinocyte growth arrest and terminal differ-
entiation. J Invest Dermatol. 1997;109:751–6.
9. Hauser PJ, Agrawal D, Hackney J, Pledger WJ. STAT3 activation
accompanies keratinocyte differentiation. Cell Growth Differ.
1998;9:847–55.
10. • Nardone B, Nicholson K, Newman M, et al. Histopathologic and
immunohistochemical characterization of rash to human epidermal
growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer
patients. Clin Cancer Res. 2010;16:4452–60. This is a study which
tries to find a relationship between histopathologic features and
biological mechanisms of skin reactions.
11. Woodworth CD, Michael E, Marker D, et al. Inhibition of the
epidermal growth factor receptor increases expression of genes
that stimulate inflammation, apoptosis, and cell attachment. Mol
Cancer Ther. 2005;4:650–8.
12. Pastore S, Mascia F, Mariotti F, et al. ERK1/2 regulates epidermal
chemokine expression and skin inflammation. J Immunol.
2005;174:5047–56.
13. Lacouture ME, Lai SE. The PRIDE (papulopustules and/or paronychia,
regulatory abnormalities of hair growth, itching, and dryness due to
epidermal growth factor receptor inhibitors) syndrome. Br J Dermatol.
2006;155:852–4.
14. • Peuvrel L, Bachmeyer C, Reguiai Z, et al. Semiology of skin
toxicity associated with epidermal growth factor receptor (EGFR)
inhibitors. Support Care Cancer. 2012;20:909–21. This is a useful
guide for clinicians to describe and manage anti-EGFR-related
skin toxicity.
15. Rosell R, Robinet G, Szczesna A, et al. Randomized phase II study
of cetuximab plus cisplatin/vinorelbine compared with cisplatin/
vinorelbine alone as first-line therapy in EGFR-expressing ad-
vanced non-small-cell lung cancer. Ann Oncol. 2008;19:362–9.
16. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial
of panitumumab plus best supportive care compared with best
supportive care alone in patients with chemotherapy-refractory
metastatic colorectal cancer. J Clin Oncol. 2007;25:1658–64.
17. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and
management of skin toxicity during therapy with epidermal growth
factor receptor inhibitors. Ann Oncol. 2005;16:1425–33.
18. Galimont-Collen AF, Vos LE, Lavrijsen AP, et al. Classification
and management of skin, hair, nail and mucosal side-effects of
epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer.
2007;43:845–51.
19. Burtness B, Anadkat M, Basti S, et al. NCCN Task Force report:
management of dermatologic and other toxicities associated with
EGFR inhibition in patients with cancer. J Natl Compr Cancer
Netw. 2009;7 Suppl 1:S5–S21. quiz S22-4.
20. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR in-
hibitors. Nat Rev Cancer. 2006;6:803–12.
21. Miettinen PJ, Berger JE, Meneses J, et al. Epithelial immaturity
and multiorgan failure in mice lacking epidermal growth factor
receptor. Nature. 1995;376:337–41.
22. Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice
guidelines for the prevention and treatment of EGFR inhibitor-
associated dermatologic toxicities. Support Care Cancer. 2011;19:
1079–95.
23. Gerber PA, Buhren BA, Cevikbas F, et al. Preliminary evidence for
a role of mast cells in epidermal growth factor receptor inhibitor-
induced pruritus. J Am Acad Dermatol. 2010;63:163–5.
24. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase
inhibitors and blocking antibodies. Lancet Oncol. 2005;6:491–500.
25. Khuntia D, Harris J, Bentzen SM. Increased oral mucositis after
IMRT versus non-IMRT when combined with cetuximab and
cisplatin or docetaxel for head and neck cancer: preliminary results
of RTOG 0234. Int J Radiat Oncol Biol Phys. 2008;72:S33.
26. Pinto C, Barone CA, Girolomoni G, et al. Management of skin
toxicity associated with cetuximab treat. in combination with che-
motherapy or radiotherapy. Oncologist. 2011;16:228–38.
27. Lacouture ME, Maitland ML, Segaert S, et al. A proposed EGFR
inhibitor dermatologic adverse event-specific grading scale from
the MASCC skin toxicity study group. Support Care Cancer. 2010;
18:509–22.
28. • Chan A, Tan EH. How well does the MESTT correlate with
CTCAE scale for the grading of dermatological toxicities associ-
ated with oral tyrosine kinase inhibitors? Support Care Cancer.
2010;19:1667–74. This analysis attempts to find a correlation
between two different ways of grading skin toxicity.
29. Ocvirk J, Rebersek M. Treatment of cetuximab-associated cutane-
ous side effects using topical application of vitamin K1 cream. J
Clin Oncol. 2009;27(15S):e15087.
30. Ocvirk J, Rebersek M, Boc M, et al. Prophylactic use of K1 cream
for reducing skin toxicity during cetuximab treatment in patients
with metastatic colorectal cancer (mCRC). J Clin Oncol. 2010;28
(15 Suppl):e14011.
31. Jatoi A, Rowland K, Sloan J. Does tetracycline prevent or palliate
epidermal growth factor receptor (EGFR) inhibitor-induced skin-
rash? Results of a phase III trial from North Central Cancer
Treatment Group (N03CB). J Clin Oncol. 2007;25:494s.
32. Scope A, Agero AL, Dusza SW, et al. Randomized double-blind
trial of prophylactic oral minocycline and topical tazarotene for
cetuximab-associated acne-like eruption. J Clin Oncol.
2007;25:5390–6.
33. • Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity
evaluation protocol with panitumumab (STEPP), a phase II,
258 Curr Colorectal Cancer Rep (2013) 9:250–260
open-label, randomized trial evaluating the impact of a pre-
emptive skin treatment regimen on skin toxicities and quality of
life in patients with metastatic colorectal cancer. J Clin Oncol.
2010;28:1351–7. This study evaluates for panitumumab the pre-
emptive and reactive treatment of skin toxicity. The preemptive
treatment showed a significant reduction of incidence.
34. Saif MW, Kaley K, Lamb L, et al. Management of skin toxicities
of anti-EGFR agents in patients with pancreatic cancer and other
GI tumors by using electronic communication: effective and con-
venient. JOP. 2010;11:176–82.
35. Perez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-
associated rash: future directions for management and investiga-
tion outcomes from the HER1/EGFR inhibitor rash management
forum. Oncologist. 2005;10:345–56.
36. Wollenberg A, Kroth J, Hauschild A, Dirschka T. Hautreaktionen
unter EGFR-Inhibitoren - Klinik und Management. Dtsch Med
Wochenschr. 2010;135:149–54.
37. Hu JC, Sadeghi P, Pinter-Brown LC, et al. Cutaneous side effects
of epidermal growth factor receptor inhibitors: clinical presenta-
tion, pathogenesis, and management. J Am Acad Dermatol.
2007;56:317–26.
38. Roe E, Garcia Muret MP, Marcuello E, et al. Description and
management of cutaneous side effects during cetuximab or
erlotinib treatments: a prospective study of 30 patients. J Am
Acad Dermatol. 2006;55:429–37.
39. Wollina U. Acute paronychia: comparative treatment with topical
antibiotic alone or in combination with corticosteroid. J Eur Acad
Dermatol Venereol. 2001;15:82–4.
40. Rao A, Bunker C. Efficacy and safety of tacrolimus ointment 0.1%
vs. betamethasone 17-valerate 0.1% in the treatment of chronic
paronychia: an unblinded randomized study. Br J Dermatol.
2010;163:208. author reply 208-9.
41. Rigopoulos D, Gregoriou S, Belyayeva E, et al. Efficacy and safety
of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1%
in the treatment of chronic paronychia: an unblinded randomized
study. Br J Dermatol. 2009;160:858–60.
42. Daniel III CR, Daniel MP, Daniel CM, et al. Chronic paronychia
and onycholysis: a thirteen-year experience. Cutis. 1996;58:397–
401.
43. Rosenbaum D, Merenstein D, Meyer F. Topical steroids more
effective than antifungals for chronic paronychia. J Fam Pract.
2002;51:824.
44. Roberts DT, Richardson MD, Dwyer PK, Donegan R. Terbinafine
in chronic paronychia and candida onychomycosis. J Dermatol
Treat. 1992;S1:39–42.
45. Rutala WA, Weber DJ. Uses of inorganic hypochlorite (bleach) in
health-care facilities. Clin Microbiol Rev. 1997;10:597–610.
46. Shu KY, Kindler HL, Medenica M, Lacouture M. Doxycycline for
the treatment of paronychia induced by the EFGR inhibitor
cetuximab. Br J Dermatol. 2006;154:191–2.
47. Hoffmann R. A 4-month, open-label study evaluating the efficacy
of eflornithine 11.5% cream in the treatment of unwanted facial
hair in women using TrichoScan. Eur J Dermatol. 2008;18:65–70.
48. Ocvirk J, Cencelj S. Management of cutaneous side-effects of
cetuximab therapy in patients with metastatic colorectal cancer. J
Eur Acad Dermatol Venereol. 2010;24:453–9.
49. Gorsky M, Epstein J, Raviv A, et al. Topical minocycline for
managing symptoms of recurrent aphthous stomatitis. Spec Care
Dentist. 2008;28:27–31.
50. Saltz L, Rubin MS, Hochster H, et al. Acne-like rash predicts
response in patients treated with Cetuximab (IMC-C225) plus
Irinotecan (CPT-11) in CPT-11-refractory colorectal cancer
(CRC) that expresses epidermal growth factor receptor (EGFR).
Clin Cancer Res. 2001;7:3766s.
51. Saltz LB, Meropol NJ, Loehrer Sr PJ, et al. Phase II trial of
cetuximab in patients with refractory colorectal cancer that
expresses the epidermal growth factor receptor. J Clin Oncol.
2004;22:1201–8.
52. Cunningham D, Humblet Y, Siena S, et al. Cetuximab (C225)
alone or in combination with irinotecan (CPT-11) in patients with
epidermal growth factor receptor (EGFR)-positive, irinotecan re-
fractory metastatic colorectal cancer (MCRC). Proc Am Soc Clin
Oncol. 2003;22:252.
53. Segaert S, Chiritescu G, Lemmens L, et al. Skin toxicities of
targeted therapies. Eur J Cancer. 2009;45 Suppl 1:295–308.
54. Van Cutsem E, Peeters M, Gelderblom H, et al. Cetuximab dose
escalation in MCRC patients with no or slight rash skin reactions on
standard treatment (Everest). Ann Oncol. 2007;18 Suppl 7:O-0034.
55. Peeters M, Siena S, Van Cutsem E, et al. Association of
progression-free survival, overall survival, and patient-reported
outcomes by skin toxicity and KRAS status in patients receiving
panitumumab monotherapy. Cancer. 2009;115:1544–54.
56. Walon L, Gilbeau C, Lachapelle JM. Éruptions acnéiformes induites
par le cétuximab. Ann Dermatol Venereol. 2003;130:443–6.
57. Perea S, Oppenheimer D, Amador M. Genotypic bases of EGFR
inhibitors pharmacological actions. Proc Am Soc Clin Oncol.
2004;196. Abstr 3005.
58. Berlin J, Neubauer M, Swanson P, et al. Panitumumab antitumor
activity in patients (pts) with metastatic colorectal cancer (mCRC)
expressing < 10% epidermal growth factor receptor (EGFr). J Clin
Oncol. 2006;24(18S):3548.
59. Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy
and symptomatic hypomagnesemia. J Natl Cancer Inst.
2005;97:1221–4.
60. Cao Y, Liao C, Tan A, et al. Meta-analysis of incidence and risk of
hypomagnesemia with cetuximab for advanced cancer.
Chemotherapy. 2010;56:459–65.
61. Petrelli F, Borgonovo K, Cabiddu M, et al. Risk of anti-EGFR
monoclonal antibody-related hypomagnesemia: systematic review
and pooled analysis of randomized studies. Expert Opin Drug Saf.
2012;11 Suppl 1:S9–S19.
62. Nie F, Shen J, Tong JL, et al. Meta-analysis: the efficacy and safety
of monoclonal antibody targeted to epidermal growth factor recep-
tor in the treatment of patients with metastatic colorectal cancer. J
Dig Dis. 2009;10:247–57.
63. Groenestege WM, Thebault S, van der Wijst J, et al. Impaired
basolateral sorting of pro-EGF causes isolated recessive renal
hypomagnesemia. J Clin Invest. 2007;117:2260–7.
64. Schlingmann KP, Weber S, Peters M, et al. Hypomagnesemia with
secondary hypocalcemia is caused by mutations in TRPM6, a new
member of the TRPM gene family. Nat Genet. 2002;31:166–70.
65. Chubanov V, Waldegger S, Mederos y Schnitzler M, et al.
Disruption of TRPM6/TRPM7 complex formation by a mutation
in the TRPM6 gene causes hypomagnesemia with secondary hy-
pocalcemia. Proc Natl Acad Sci USA. 2004;101:2894–9.
66. Tejpar S, Piessevaux H, Claes K, et al. Magnesium wasting associ-
ated with epidermal-growth-factor receptor-targeting antibodies in
colorectal cancer: a prospective study. Lancet Oncol. 2007;8:387–94.
67. Torralbo A, Portoles J, Perez Perez AJ, Barrientos A.
Hypomagnesemic hypocalcemia in chronic renal failure. Am J
Kidney Dis. 1993;21:167–71.
68. Fakih MG, Wilding G, Lombardo J. Cetuximab-induced hypo-
magnesemia in patients with colorectal cancer. Clin Colorectal
Cancer. 2006;6:152–6.
69. Dai Q, Shrubsole MJ, Ness RM, et al. The relation of magnesium
and calcium intakes and a genetic polymorphism in the magnesium
transporter to colorectal neoplasia risk. Am J Clin Nutr.
2007;86:743–51.
70. Perrin C, Fabre C, Raoul JL, Boucher E. Behavioral disorders
secondary to profound hypomagnesemia in a patient given
cetuximab for metastatic colorectal cancer hypomagnesemia due
to cetuximab treatment. Acta Oncol. 2006;45:1135–6.
Curr Colorectal Cancer Rep (2013) 9:250–260 259
71. Fakih M. Management of anti-EGFR-targeting monoclonal
antibody-induced hypomagnesemia. Oncology (Williston Park).
2008;22:74–6.
72. Vincenzi B, Santini D, Galluzzo S, et al. Early magnesium reduc-
tion in advanced colorectal cancer patients treated with cetuximab
plus irinotecan as predictive factor of efficacy and outcome. Clin
Cancer Res. 2008;14:4219–24.
73. •• Vincenzi B, Galluzzo S, Santini D, et al. Early magnesium modifi-
cations as a surrogatemarker of efficacy of cetuximab-based anticancer
treatment in KRASwild-type advanced colorectal cancer patients. Ann
Oncol. 2011;22:1141–6. This is one of few studies evaluating the
predictive role of early decrease in magnesium concentration for
anti-EGFR efficacy. As shown in this study, hypomagnesemia is related
to response rates, time to progression, and overall survival.
74. Vickers MM, Karapetis CS, Tu D, et al. Association of hypomag-
nesemia with inferior survival in a phase III, randomized study of
cetuximab plus best supportive care versus best supportive care
alone: NCIC CTG/AGITG CO.17. Ann Oncol. 2013;24:953–60.
75. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study
of irinotecan and 5-FU/FAwith or without cetuximab in the first-line
treatment of patients with metastatic colorectal cancer (mCRC): The
CRYSTAL trial. J Clin Oncol. 2007;25(18 Suppl):4000.
76. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III
study of panitumumab with fluorouracil, leucovorin, and
irinotecan (FOLFIRI) compared with FOLFIRI alone as second-
line treatment in patients with metastatic colorectal cancer. J Clin
Oncol. 2010;28:4706–13.
77. •• Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III
trial of panitumumab with infusional fluorouracil, leucovorin, and
oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treat-
ment in patients with previously untreated metastatic colorectal
cancer: the PRIME study. J Clin Oncol. 2010;28:4697–705. This is
the most important study evaluating efficacy and toxicity deriving
from the combination of panitumumab and chemotherapy.
78. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced ana-
phylaxis and IgE specific for galactose-alpha-1,3-galactose. N
Engl J Med. 2008;358:1109–17.
79. • Siena S, Glynne-Jones R, Adenis A, et al. Reduced incidence of
infusion-related reactions in metastatic colorectal cancer during
treatment with cetuximab plus irinotecan with combined cortico-
steroid and antihistamine premedication. Cancer. 2010;116:1827–
37. This study identified the proper premedication to prevent
cetuximab-related infusion reactions by premedication.
80. Nielsen DL, Pfeiffer P, Jensen BV. Re-treatment with cetuximab in
patients with severe hypersensitivity reactions to cetuximab. Two
case reports. Acta Oncol. 2006;45(8):1137–38.
81. Saif MW, Kim R. Incidence and management of cutaneous toxic-
ities associated with cetuximab. Expert Opin Drug Saf.
2007;6:175–82.
82. Saif MW, Peccerillo J, Potter V. Successful re-challenge with
panitumumab in patients who developed hypersensitivity reactions
to cetuximab: report of three cases and review of literature. Cancer
Chemother Pharmacol. 2009;63:1017–22.
83. Power DG, Shah MA, Asmis TR, et al. Safety and efficacy of
panitumumab following cetuximab: retrospective review of the
Memorial Sloan-Kettering experience. Invest New Drugs.
2010;28:353–60.
84. Barber NA, Ganti AK. Pulmonary toxicities from targeted thera-
pies: a review. Targ Oncol. 2011;6:235–43.
85. Chua W, Peeters M, Loneragan R, Clarke S. Cetuximab-
associated pulmonary toxicity. Clin Colorectal Cancer. 2009;8(2):
118–20.
86. Giusti RM, Shastri K, Pilaro AM, Fuchs C, Cordoba-Rodriguez R,
Koti K, et al. U.S. Food and Drug Administration approval:
panitumumab for epidermal growth factor receptor-expressing
metastatic colorectal carcinoma with progression following
fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemo-
therapy regimens. Clin Cancer Res. 2008;14(5):1296–302.
260 Curr Colorectal Cancer Rep (2013) 9:250–260
